Related Experiment Video
Updated: Jul 31, 2026
12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
Liver transplantation for primary sclerosing cholangitis
1Multi-Organ Transplant Program, London Health Sciences Centre, London, Ontario, Canada. esolano@shaw.ca
Transplantation Proceedings
|November 13, 2003
Summary
Liver transplantation (LT) is effective for primary sclerosing cholangitis (PSC). Survival rates are comparable to other conditions, but recurrent PSC and chronic rejection can impact long-term graft survival.
Area of Science:
- Hepatology
- Transplant Surgery
- Gastroenterology
Background:
- Primary sclerosing cholangitis (PSC) is a chronic liver disease leading to end-stage liver disease.
- Liver transplantation (LT) is a treatment option for PSC patients.
- Canadian center data from 1984-2002 was analyzed.
Purpose of the Study:
- To evaluate the outcomes of liver transplantation (LT) for primary sclerosing cholangitis (PSC).
- To compare patient and graft survival in PSC patients undergoing LT with non-PSC patients.
Main Methods:
- Retrospective analysis of 111 patients with PSC who underwent LT between 1984 and 2002.
- Comparison of survival data with non-PSC patients transplanted during the same period.
Main Results:
- Patient survival at 1, 3, 5, and 10 years was 84.5%, 84.5%, 83.4%, and 68.9%, respectively.
- Graft survival at 1, 3, 5, and 10 years was 80.8%, 79.8%, 72.7%, and 55.3%, respectively.
- Survival rates were comparable to non-PSC patients, but long-term graft survival may be lower.
Conclusions:
- Liver transplantation is an effective therapy for primary sclerosing cholangitis.
- Recurrent PSC and chronic rejection are significant factors in graft loss after LT for PSC.
- While overall survival is comparable, long-term graft survival in PSC patients may be reduced.
